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Pseudoxanthoma Elasticum Is a Recessive Disease
Characterized by Compound Heterozygosity
Franziska Ringpfeil1,4, Kelly McGuigan1,4, Lauren Fuchsel1, Heidi Kozic1, Margarita Larralde2,
Mark Lebwohl3 and Jouni Uitto1
Pseudoxanthoma elasticum (PXE) is caused by mutations in the ABCC6 gene. Historically, PXE has been
suggested to be inherited either in an autosomal dominant or autosomal recessive manner. To determine the
exact mode of inheritance of PXE and to address the question of phenotypic expression in mutation carriers,
we identified seven pedigrees with affected individuals in two different generations and sequenced the entire
coding region of ABCC6 in affected individuals, presumed carriers with a limited phenotype and unaffected
family members. Two allelic mutations were identified in each individual with unambiguous diagnosis of PXE, as
well as in those with only minimal clinical signs suggestive of PXE but with positive skin biopsy. Missense
mutations were frequently detected in the latter cases. In conclusion, PXE is inherited in an autosomal recessive
manner and presence of disease in two generations is due to pseudodominance.
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INTRODUCTION
Pseudoxanthoma elasticum (PXE; OMIM 264800 and
177850) is a heritable multisystem disorder with cutaneous,
ophthalmologic, and cardiovascular manifestations (McKusick,
1972; Neldner, 1988; Uitto and Pulkkinen, 2002). There is
marked clinical heterogeneity, and patients even within
the same family may differ in disease severity as well as in
the number of organ systems involved. PXE is caused by
mutations in the ABCC6 gene located on chromosome
16p13.1 (Bergen et al., 2000; Le Saux et al., 2000; Ringpfeil
et al., 2000). This gene encodes MRP6, an ATP-binding
cassette transmembrane transporter protein expressed pri-
marily in the liver and the kidneys (Kruh and Belinsky, 2003).
Since the discovery of ABCC6 as the gene harboring
mutations in PXE, molecular studies have suggested an
autosomal recessive mode of inheritance in the majority of
PXE families studied (Le Saux et al., 2001; Ringpfeil et al.,
2001b; Chassaing et al., 2004, 2005; Plomp et al., 2004).
However, the exact mode of inheritance of PXE has remained
controversial for several reasons. First, early clinical and
epidemiologic studies, particularly in the United Kingdom,
suggested that a large portion of families display autosomal
dominant inheritance, based on clinical observations of affected
individuals in two subsequent generations (Pope, 1974).
Second, more recent studies have suggested that heterozygous
carriers of ABCC6 mutations in families with a history of PXE
may have subclinical disease, that is, positive skin biopsy in the
absence of overt clinical lesions and with asymptomatic or
minimally symptomatic angioid streaks (Bacchelli et al., 1999;
Sherer et al., 2001). In addition, the pattern of inheritance is
often difficult to decipher from the family pedigree owing to
delayed onset of symptoms, frequently not evident until the
second or third decade of life (Neldner, 1988).
We have identified seven families with clinical features
suggestive of PXE in individuals in two generations. We
performed mutation analysis by direct sequencing of the
ABCC6 gene in these families to clarify the exact mode of
inheritance at the molecular level.
RESULTS
Clinical features
The nuclear pedigrees of the seven families with affected
individuals in two generations are depicted in Figure 1. All
patients were examined at least by one of the authors, and
investigations included skin biopsy and ophthalmologic
examination with fluorescent angiography. The clinical
findings in the affected individuals, including skin findings,
the presence of angioid streaks, and evidence of vascular
disease, together with skin biopsy results are summarized in
Table S1. Families 1–3 included presumed obligate hetero-
zygous carriers with asymptomatic or mildly symptomatic
angioid streaks and positive skin biopsy in the parent
generations (for clinical details of Family 1, see Ringpfeil
et al., 2000). In Family 4, a father and a son were clearly
affected with PXE. Family 5 depicted a clinically affected
paternal grandmother of an affected child (Larralde et al.,
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2002). Families 6 and 7 were consanguinous and featured
clinically affected individuals in two subsequent generations
(for details of Family 6, see Ringpfeil et al., 2000).
Genotypic data
Mutation analysis of the ABCC6 gene resulted in detection of
two allelic mutations in each affected individual as well as in
those presumed to be heterozygous carriers with subclinical
phenotype (Figure 1 and Table S1). A total of 11 distinct
ABCC6 mutations were discovered in the 34 alleles of these
individuals. Five of the alleles harbored the recurrent R1141X
mutation, which is prevalent in Caucasian populations, six of
the alleles contained the R1138W mutation, and seven
alleles harbored the deletion mutation del23–29, all of which
have been previously reported in a number of families with
PXE (Le Saux et al., 2001; Ringpfeil et al., 2001a; Uitto et al.,
2001; Pulkkinen et al., 2002; Chassaing et al., 2004). Among
the other mutations identified, three were novel missense
mutations: W218C, T811M, and R1164Q. In addition,





























Figure 1. Pedigrees of seven families with PXE in two generations. Solid symbols denote a definite diagnosis of PXE; shaded symbols reflect minimal cutaneous
and/or ophthalmological symptoms or a histopathological diagnosis of PXE based on skin biopsy. Double lines denote consanguinity. The corresponding
mutations are indicated below each individual examined. The diagnosis of an individual marked by ? in Family 2 is uncertain.
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noted in the proband of Family 4. The previously undescribed
missense mutations were considered pathogenic, as they
were not found in at least 200 alleles of unrelated healthy
controls.
In Family 1, the two affected daughters of a clinically
unaffected mother and an affected father were compound
heterozygotes (R1141X/del23–29), and the parents were
carriers of the corresponding mutations. In addition, the
father with asymptomatic angioid streaks, evidence of
coronary artery disease, history of gastrointestinal bleeding,
and positive skin biopsy, but no clinically obvious skin
involvement, was compound heterozygous for R1141X and a
novel missense mutation T811M. In Family 2, the three
children were compound heterozygotes with two different
combinations (del23–29/W218C and R391G/W218C). The
mother with minimal clinical signs but with a positive skin
biopsy was compound heterozygous for two of these
mutations (del23–29/R391G) and manifested with asympto-
matic angioid streaks and hypertension. However, the father,
a heterozygous carrier of the W218C mutation, as well as the
maternal grandmother, carrier of the del23–29 mutation,
were clinically unaffected. In Family 3, the clinically affected
son was homozygous for the del23–29 mutation, whereas the
mother manifesting with vision loss, intermittent claudica-
tion, stroke, and hypertension was a compound heterozygote
for del23–29/R391G mutations. She had not been diagnosed
with PXE prior to this study. The son had presumably
inherited the other del23–29 allele from the clinically
unaffected father. In Family 4, the two affected individuals,
a father and a son, were compound heterozygotes, both for
R1141X mutation in one allele, in combination with either
F568S (father) or W1324X (son). In Family 5, the proband was
compound heterozygote for R1164Q/R518X, the missense
mutation being inherited from the clinically unaffected father
while the nonsense mutation was either a de novo mutation
or reflected germline mosaicism in the clinically unaffected
mother whose peripheral blood DNA did not carry this
mutation. The grandmother of the proband was homozygous
for the R1164Q mutation. Segregation of the mutant alleles in
Families 6 and 7 suggested that the homozygosity for the
R1138W mutation (Family 6) and compound heterozygosity
for the R391G/R1138W mutations (Family 7) in affected
individuals in two subsequent generations were due to
consanguinity, a conclusion supported by examination of
the family pedigrees (see Figure 1) and by haplotype analysis
(data not shown).
The presence of different combinations of mutations in
these families could suggest that the carrier frequency of
mutations in the ABCC6 gene may be higher than previously
suspected, resulting in occurrence of different compound
heterozygous mutations in the same family, with a different
degree of clinical involvement. However, probing the two
most common mutations in ABCC6, namely R1141X and
deletion of exons 23–29 in 254 control alleles of Caucasian
origin, revealed no carriers (data not shown).
Collectively, our data indicate that individuals with
unambiguous diagnosis of PXE, as well as those presenting
with minimal manifestations suggestive of PXE and positive
skin biopsy, examined in our study, harbor two mutations in
the ABCC6 gene.
DISCUSSION
Since the availability of DNA testing in PXE, an accumulating
body of evidence has suggested that PXE is inherited
primarily in an autosomal recessive inheritance pattern, and
that autosomal dominant PXE in many cases reflects
pseudodominance. Despite the overwhelming evidence to
the contrary to date, some practitioners still believe in an
autosomal dominant form of PXE and initiate work up and
counseling accordingly. Those beliefs were fostered by early
publications that suggested the presence of both autosomal
dominant and autosomal recessive forms of PXE (Pope, 1974,
1975). In particular, studies canvassing the PXE patient
population in the United Kingdom reported that the majority,
B53% of the 121 families examined, showed autosomal
dominant inheritance with disease presenting in two sub-
sequent generations, as suggested by clinical observation but
not verified in all cases by diagnostic skin biopsy (Pope,
1974). Subsequently, examination of a cohort of 100 patients
in the United States concluded that the majority of cases,
490%, demonstrate autosomal recessive inheritance, and
that autosomal dominant inheritance, as evidenced at the
time by the presence of affected individuals in two
generations, is rare (Neldner, 1988). Many of the cases were
sporadic with an unknown mode of inheritance. In a recent
report, Plomp et al. (2004) re-examined their PXE families
from the Netherlands with previously reported autosomal
dominant disease and reviewed the existing literature
(1966–2003) on several other families. Through clinical,
genealogical, and molecular genetic examination, they re-
classified the mode of inheritance as autosomal recessive in
all but one of their families, in which a second mutation
could not be identified. They concluded that autosomal
dominant inheritance in PXE may exist, but is much more rare
than previously thought. As the current detection rate for
mutations in the ABCC6 gene by direct sequencing has been
reported to be in the range of 70–100%, it is reasonable to
assume that the second mutation in their family evaded
detection, although this possibly was dismissed by the
authors (Plomp et al., 2004). On another note, reports on
minimal symptoms in obligate carriers were based on
establishing the presence of a single mutation in a first-
degree relative of a PXE patient, yet the obligate carriers were
not examined for additional, independently inherited coding
changes in the ABCC6 gene (Bacchelli et al., 1999).
In this study, we have examined seven families with
evidence of PXE in two different generations. In four of the
families (nos. 4–7) there were clearly affected individuals in
two generations, as determined by characteristic clinical
findings, and positive skin biopsy demonstrating abnormal,
calcified elastic fibers. In two of the families (nos. 6 and 7),
pseudodominant inheritance was caused by consanguinity, a
phenomenon that has recently been highlighted in other PXE
families as well (Ringpfeil et al., 2000; Chassaing et al.,
2004). In Families 4 and 5, compound heterozygosity due to
two different combinations of mutations was observed. In
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Families 1–3, individuals with clearcut diagnosis of PXE were
noted, and in each family one of the parents had minimal
clinical manifestations but positive skin biopsy and they were
found to be compound heterozygous for ABCC6 mutations. It
is of interest that in Family 2, the eldest son and the daughter
had a clearcut clinical diagnosis of PXE, yet the second son,
upon examination by a dermatologist and an ophthalmolo-
gist, showed no clinical evidence of PXE at the age of 37
years even though he was compound heterozygous for
R391G/W218C mutations. These mutations are apparently
pathogenic in a recessive manner, as they, in combination
with the del23–29 mutation, result in severe phenotype in the
older and younger siblings of this individual (Figure 1). This
individual, from whom no skin biopsy was available, may
therefore represent a presymptomatic, clinically undetectable
form of PXE, and his disease manifestations may be delayed
beyond his current age. Thus, in each patient examined in
this study, even in cases with the most limited form of the
disease, the clinical manifestations are a result of the
presence of two mutations in the affected individuals. These
observations emphasize the phenotypic heterogeneity in PXE
and suggest the possibility that intragenic ABCC6 polymorph-
isms and/or other modulating genes influence the clinical
presentations.
Collectively, our findings strongly imply that PXE follows
strictly an autosomal recessive mode of inheritance. This
conclusion has been reinforced by recent observations on
mice in which the Abcc6 gene has been inactivated by
targeted ablation (Gorgels et al., 2005; Klement et al., 2005).
Specifically, in a study reported by us (Klement et al., 2005),
heterozygous þ / mice, similar to their wild-type litter-
mates, displayed no evidence of tissue calcification, while/
mice readily showed extensive calcification of skin, mid-
sized arteries, retina, and other tissues, recapitulating PXE.
The findings of our study have clear implications for
genetic counseling. First, our studies establish that PXE is
inherited in an autosomal recessive manner, thus providing
basis for appropriate counseling for the risk of re-occurrence
of PXE in families with at least one previously affected
individual. In this context, it should be noted that identifi-
cation of ABCC6 mutations in an affected child with PXE and
his/her heterozygous carrier parents allows presymptomatic
diagnosis of this condition in siblings in whom the
manifestations of PXE may be delayed even beyond the
usual time span of manifestations in the second or third
decade of life. Finally, our observations suggest that
pseudodominance is relatively frequent in PXE, a notion that
the health-care personnel providing genetic counseling
should be aware of.
MATERIALS AND METHODS
Patient population
Seven families with either the diagnosis of PXE in two generations or
PXE in one generation and an obligate heterozygote with limited
phenotype in another were selected from a cohort of over 70 families
with PXE in a research database. The diagnostic criteria for PXE
consisted of cutaneous yellowish papules and plaques in predilection
sites together with angioid streaks and/or evidence of cardiovascular
disease. Individuals with positive skin biopsy and lack of clinical
skin manifestations, but having asymptomatic angioid streaks and/or
cardiovascular disease, were considered minimally affected. All
families consisted of two or more affected individuals (Figure 1).
Informed consent was obtained from all individuals conforming to
the University’s Institutional Review Board, and the experiments
were performed according to the Helsinki Principles. Patients were
subjected to dermatological, ophthalmological, and cardiologic
examination (Table S1). All patients were seen by at least one of
the authors and had a skin biopsy (hematoxylin and eosin and von
Kossa stains). The presence of angioid streaks was verified by
fundoscopy. Blood was obtained from all affected individuals and
their unaffected family members when available. Control DNA was
also obtained from 104 unrelated, population-matched controls
using the above ethical guidelines.
Genotype analysis
Genomic DNA was isolated from peripheral blood leukocytes using
standard protocols. The 31 exons and flanking intronic sequences of
the ABCC6 gene were amplified by PCR, followed by automated
dideoxy nucleotide sequencing (Pulkkinen et al., 2001; Ringpfeil
et al. 2001b). New mutations were confirmed by restriction enzyme
digests of 50 unrelated, unaffected controls. The segregation of
pathogenetic mutations within families was determined by restriction
enzyme digestion and/or direct nucleotide sequencing.
Haplotype analysis
Haplotyping was performed in individuals who were homozygous
for ABCC6 mutations to determine consanguinity. Twelve micro-
satellite markers spanning 3 cM around the ABCC6 locus were PCR
amplified. PCR products were end labeled with [g-32P]ATP and
examined on 6% polyacrylamide sequencing gels. Up to 25
intragenic single nucleotide polymorphisms were analyzed by direct
sequencing or restriction enzymatic digestion.
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